Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Outline of Final Research Achievements |
We established a method to generate erythropoietin (EPO)-producing cells from human induced pluripotent stem cells (hiPSCs) that showed increased EPO expression and secretion in response to low oxygen conditions. The EPO protein secreted from hiPSC-derived EPO-producing cells (hiPSC-EPO cells) induced the erythropoietic differentiation of umbilical cord blood progenitors in vitro. Furthermore, injection of EPO protein from hiPSC-EPO cells improved renal anemia in adenine-induced renal failure mice. In conclusion, hiPSC-EPO cells may provide a novel therapeutic agent for anemia.
|